Patent Watch: Saffran v. Johnson & Johnson

by BakerHostetler
Contact

To be sure, a prosecution disclaimer requires "clear and unambiguous disavowal of claim scope," but applicants rarely submit affirmative disclaimers along the lines of "I hereby disclaim the following . . ." during prosecution and need not do so to meet the applicable standard.

On April 4, 2013, in Saffran v. Johnson & Johnson, the U.S. Court of Appeals for the Federal Circuit (Lourie,* Moore, O'Malley) reversed the district court's judgment that Johnson & Johnson and Cordis Corp. infringed U.S. Patent No. 5,653,760, which related to the treatment of injured tissues within human or animal bodies involving the way injured tissues are joined and macromolecules are directed to promote healing. The Federal Circuit stated:

The term "device" appears in every claim of the '760 patent -- in the preamble and body of independent claim 1, in the bodies of independent claims 8 and 15, and at least by reference in each of the dependent claims. In its Claim Construction Order, the district court nonetheless concluded that, as used in the '760 patent, the term "device" serves only as non-limiting preamble language that does not require a sheet and "merely gives a descriptive name to the set of limitations in the body of the claim that set forth the invention." . . . We conclude that Saffran's statements during prosecution of the '760 patent limit "device" to a continuous sheet. On multiple occasions during prosecution, Saffran sought to distinguish prior art by representing to the examiner that "[t]he device used is a sheet rather than a pre formed chamber (Gaskill)." Saffran contends that his statements merely disclaimed the rigid pre-formed chambers disclosed in U.S. Patent 4,911,717 ("Gaskill") without further limiting the invention to a sheet. While Saffran surely disclaimed preformed chambers during prosecution, we disagree that his statements have such limited import. Saffran's arguments to the examiner presented two bases for distinguishing Gaskill: (i) that his device is a sheet, and (ii) that his device is not a pre-formed chamber. Even if, as Saffran suggests, the examiner had relied only on the latter, that would not annul the remainder of his statement. "Rather, as we have made clear, an applicant's argument that a prior art reference is distinguishable on a particular ground can serve as a disclaimer of claim scope even if the applicant distinguishes the reference on other grounds as well." Furthermore, the record before us makes clear that the examiner shared Saffran's stated view of the claimed device as a continuous sheet. In recording his reasons for allowance, the examiner noted that "[t]he claimed invention embodies a unique method of [macromolecular restraint] using a single flexible minimally porous sheet layer."

To be sure, a prosecution disclaimer requires "clear and unambiguous disavowal of claim scope," but applicants rarely submit affirmative disclaimers along the lines of "I hereby disclaim the following . . ."during prosecution and need not do so to meet the applicable standard. In this case, Saffran's unqualified assertion that "the device used is a sheet" extends beyond illuminating "how the inventor understood the invention," to provide an affirmative definition for the disputed term. Given such definitive statements during prosecution, the interested public was entitled to conclude that the "device" recited in the claims of the '760 patent is a continuous sheet.

Saffran's arguments alleging that the '760 patent contains contrary embodiments are not persuasive. Saffran first contends that the "spray" embodiment disclosed in the '760 patent does not yield an unbroken sheet but forms a layer only where it contacts bone or some other solid surface, such as the struts of a stent. But the record belies that assertion. The figures illustrating the spray embodiment show a spray nozzle depositing a continuous, unbroken sheet that spans open gaps between individual bone fragments. More fundamentally, and as Saffran acknowledged during trial, the '760 patent never mentions spraying the device onto a stent or any other support substrate except the injured tissue itself. On that very basis, in fact, Saffran attempted to distinguish his spray embodiment from a prior art vascular graft (disclosed in U.S. Patent 5,152,782 ("Kowligi")) that was subjected to spray coating before implantation: "The critical difference here is that Kowligi disclose[s] a way to make their device, while I disclose a way to deploy mine." The '760 patent's spray embodiment thus concerns depositing a continuous sheet of material onto injured tissue, not preparing a support structure such as a stent for later implantation into a patient.

The specification supports this conclusion. Throughout its specification, the '760 patent consistently describes the disclosed "device" as a sheet, whether wrapped around a stent, affixed to a fractured bone, or applied as a spray. Extensive, consistent usage in the specification therefore suggests that the claimed "device" should be understood as a sheet, which, rather than confining the term to a single embodiment, would accord with every embodiment and description presented in the '760 patent, not to mention the prosecution history.

Furthermore, the '760 patent emphasizes macromolecular containment as a key feature of the invention, and, in the specific context of vascular stents, expressly relies on the sheet to distinguish the claimed device from prior art open mesh stents. The specification describes the device's ability to restrain tissue macromolecules near the site of injury as a "cardinal" and "exceedingly important" feature of the invention. The specification also criticizes prior art stents as unable to restrain macromolecules between the stent and the vessel wall; according to the '760 patent, prior art stents "are porous meshes" characterized by holes so large that "both cells and large macromolecules are free to move through them." In short, the specification makes clear that restraining tissue macromolecules is not only a key feature of the invention, but also one that open mesh stents cannot provide. Therefore, reading the claim term "device" to both require a sheet and exclude stents having open mesh holes "most naturally aligns with the patent's description of the invention." . . .

Under the correct construction of the term "device," Cordis cannot infringe the asserted apparatus or method claims unless its accused stent products include a continuous sheet and lack uncovered holes in the stent mesh. The accused Cordis stents all exhibit a metallic mesh structure, their struts coated with a thin layer comprising polymer and sirolimus. But that layer is akin to paint on a chain link fence, not a continuous sheet wrapped around the mesh, and open holes remain between the struts of the accused devices -- as Saffran has acknowledged. Therefore, no reasonable jury could conclude that Cordis's accused stents infringe the asserted claims of the '760 patent, and Cordis is entitled to a judgment of noninfringement as a matter of law.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:

BakerHostetler
Contact
more
less

BakerHostetler on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
Feedback? Tell us what you think of the new jdsupra.com!